Foote R L, Schild S E, Thompson W M, Buskirk S J, Olsen K D, Stanley R J, Kunselman S J, Schaid D J, Grill J P
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905.
Cancer. 1994 May 15;73(10):2638-47. doi: 10.1002/1097-0142(19940515)73:10<2638::aid-cncr2820731028>3.0.co;2-h.
The authors determined the patterns of treatment failure in patients treated with surgery alone or surgery combined with postoperative radiation therapy for squamous cell carcinoma of the tonsil.
Seventy-two patients underwent surgery alone (56) or surgery and postoperative adjuvant radiation therapy (16). All patients were followed up until death (40 patients) or for a minimum of 3.5 years. For patients treated with surgery alone, clinic notes, operative notes, and pathology reports and slides were reviewed to identify clinical or pathologic predictors of recurrence above the clavicles, cause-specific survival, and overall survival. For patients undergoing postoperative adjuvant radiation therapy, demographic, treatment, and pathologic variables were analyzed to identify factors associated with control of disease above the clavicles, disease-free survival, and overall survival.
The main pattern of treatment failure was above the clavicles. It occurred in 39% of patients treated with surgery alone and was significantly related (P = 0.002) to the overall clinical TNM stage. Disease recurrence above the clavicles occurred in 31% of patients undergoing surgery and postoperative adjuvant radiation therapy, despite their more advanced neck disease. Five-year overall survival for patients with clinical Stage III and IV disease who were treated with surgery and post-operative adjuvant radiation therapy was 100% and 78%, respectively. Five-year overall survival for patients treated with surgery alone who had clinical Stage III, IVA, or IVB disease was 56%, 43%, and 50%, respectively.
We recommend postoperative adjuvant radiation therapy for patients with clinical Stage III or IV squamous cell carcinoma of the tonsil who have undergone complete surgical resection because this appears to improve control of disease above the clavicles and overall survival.
作者确定了单纯手术治疗或手术联合术后放疗的扁桃体鳞状细胞癌患者的治疗失败模式。
72例患者接受了单纯手术(56例)或手术及术后辅助放疗(16例)。所有患者均随访至死亡(40例患者)或至少3.5年。对于单纯手术治疗的患者,回顾临床记录、手术记录、病理报告和切片,以确定锁骨上复发的临床或病理预测因素、特定病因生存率和总生存率。对于接受术后辅助放疗的患者,分析人口统计学、治疗和病理变量,以确定与锁骨上疾病控制、无病生存率和总生存率相关的因素。
主要治疗失败模式发生在锁骨上。在单纯手术治疗的患者中,39%出现这种情况,且与总体临床TNM分期显著相关(P = 0.002)。接受手术及术后辅助放疗的患者中,31%出现锁骨上疾病复发,尽管他们的颈部疾病更为严重。接受手术及术后辅助放疗的临床III期和IV期疾病患者的5年总生存率分别为100%和78%。单纯手术治疗的临床III期、IVA期或IVB期疾病患者的5年总生存率分别为56%、43%和50%。
我们建议对已接受完整手术切除的临床III期或IV期扁桃体鳞状细胞癌患者进行术后辅助放疗,因为这似乎能改善锁骨上疾病的控制和总生存率。